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Abstract
Background: A review of newly arriving refugees referred to the local health department for
latent tuberculosis infection (LTBI) treatment during 2013-2015 revealed a treatment gap of 73%,
supporting the need to identify new approaches to treat vulnerable populations and mirrored results
in the literature.
Objectives: 1) Describe an advanced practice registered nurse (APRN) led alternative approach to
LTBI treatment in the refugee population; and 2) evaluate the impact of a 12-week regimen for LTBI
on treatment acceptance, adherence and completion.
Methods: During the initial health screening visit, treatment options were provided for those identified
with LTBI consisting of either a 12-week regimen requiring weekly directly observed therapy (DOT)
or the traditional 9-month treatment.
Results: During March-December 2016, 50 refugees were referred and 24/50 were offered a 12week regimen of Rifapentine and Isoniazid, administered with DOT. 23 of the 24 or 96% completed
the entire treatment course.
Conclusions: The new LTBI clinic process resulted in an increase in treatment acceptance and
completion compared with the historic rate of 27%.
Implications for Nursing: APRN initiatives such as this can result in positive benefits to patients and
communities while serving to advance the nursing profession in all practice settings
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Background
The epidemiology of Mycobacterium tuberculosis infection
continues to change with an increasing number of cases
identified among those born outside the United States. LoBue
and Mermin (2017), and Tsang and colleagues (2017) described
the importance of identifying the presence of latent tuberculosis
infection (LTBI) among the foreign-borne and the need to
address both active and latent infection as part of a national
public health strategy. The United States (US) has historically
resettled approximately 100,000 refugees and other entrants
each year (ORR, 2016). LTBI has been an area of concern at
the University of Louisville Global Health Center (UL-GHC) due
to the consistent rates of infection present among the resettling
refugee population in Kentucky. According to data collected
by the UL-GHC, overall rates of LTBI among the refugee and
immigrant population resettling in Kentucky was 9% versus
5% among native-borne US citizens (Carrico, Goss, Wiemken,
Bosson, Peyrani, Mattingly, et al., 2017). Reports demonstrating
these rates of LTBI identified in refugees resettling in Kentucky
over the course of the past five years can be found at http://
globalhealth.center/rhp/state.php.
Using data available in the UL-GHC Arriving Refugee
Informatics SurVeillance and Epidemiology (ARIVE)
database, a significant disconnect between LTBI treatment
recommendations and completion was identified. During
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January 2013-December 2014, 45 (8%) refugees were diagnosed
with LTBI. All were referred to the local health department
and provided appointments at dates and times agreeable to
the refugee patient. Of those, 25/45 (56%) kept the health
department appointment and 20/45 (44%) agreed to initiation
of treatment for LTBI. Of those 20 who agreed to treatment,
12/20 (60%) completed treatment. That means of the 45 eligible
for LTBI treatment, only 12/45 (27%) were treated resulting in
a management gap of 73% (Figure 1). Barriers to treatment
data previously gathered by UL-GHC researchers included: 1)
lack of knowledge about LTBI and its importance to general
health, 2) possibility of reactivation of the disease, 3) need for
treatment despite lack of recognizable symptoms, 4) language
differences among providers, 5) work schedule conflicts, and
6) transportation to appointments as critical factors needing
attention.
Further, refugees cited difficulties in accessing
medication as a barrier to initiation as well as completion of the
recommended LTBI treatment. These findings were consistent
with treatment barrier information identified in the literature
(Colson, Franks, Sondengam, Hirsch-Moverman, & El-Sadr,
2010; Wieland, Weis, Yawn, Sullivan, Millington, Smith et
al., 2012). The poor rate of treatment completion combined
with the many barriers to treatment acceptance prompted a
complete review of existing LTBI management practices for
this vulnerable population. The result was implementation of a
Copyright: © 2019 The author(s). This is an open access article distributed under
the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0),
which permits unrestricted use, distribution, and reproduction in
any medium, provided the original author and source are credited.

refugees experienced in healthcare or health education. These
GHNs were brought into the LTBI clinic process as a means
of promoting effective communication and culturally tailored
care for the varied refugee populations targeted for LTBI
treatment. Recognizing the risks associated with incomplete
LTBI treatment (e.g., development of drug resistance), the
12-week INH/RPT treatment regimen promoted by CDC was
chosen as the regimen of choice for the refugee population given
their propensity for secondary migration and subsequent loss to
follow-up (Greenwood & Warriner, 2011). A new clinic led by an
APRN, supported by other APRNs and GHNs was implemented.
Figure 1 Latent Tuberculosis Infection (LTBI) Management Gap

new clinic process led by an advanced practice registered nurse
(APRN) expert in care for the refugee population and infectious
diseases.
The objectives of this project were: 1) describe this new LTBI
clinic, and 2) share the results of its first six months of operation.

Methods
This new approach to LTBI treatment provided in the UL-GHC
refugee-centered medical home involved three core components
and formed the basis for a pilot study assessing effectiveness. A
medical home is defined by the Agency for Healthcare Reseach
and Quality (AHRQ) as a location for care that is organized in
a way that services are accessible, organized and of sufficient
quality (AHRQ 2012). The three core components included: 1)
initiation of an LTBI clinic led by an advanced practice registered
nurse (APRN), 2) use of global health navigators (GHN) as key
support personnel in the LTBI care and treatment plan, and 3)
use of a 12-week Isoniazid/Rifapentine (INH/RPT) treatment
regimen with directly observed therapy (DOT) (Centers for
Disease Control and Prevention [CDC], 2013). DOT involves
provision of medication to the recipient with visualization of
medication self-administration. Therefore, DOT is a process
that does not require a licensed healthcare worker as the patient
is administering the medication to themselves.
The LTBI clinic was conceptualized by a group of APRNs
with expertise in refugee healthcare, infectious diseases,
program development and evaluation in late 2015. A lead
APRN designed the clinic and workflow process with an
emphasis on identification of specific competencies and skill
sets needed by all members of the care team. The UL-GHC
had recently initiated a GHN program that engaged former
Figure 2. Directly Observed Therapy Log (DOT): 12-Dose Isoniazid-Rifapentine LTBI Treatment

Name:______________________________ DOB:_____________
Preferred Language:__________________ Sex: M F Weight__________lbs Height__ft__inches
Ethnicity: Hispanic Non-Hispanic
Treatment Reason:  Refugee  Civil Surgeon  Travel  Employee Health  550 Clinic  Other_______________
Dose: INH______mg Tab strength________ INH # tabs______ Dose: RPT______mg Tab strength________ RPT # tabs______
Current Medications:
Medication Allergies:___________________________________________________________ NKDA_______ Food Allergies_______________________________________________________
_________________________________________

*For events listed below, check if event/symptom occurs, otherwise leave blank. (The event may have occurred in the past, after a previous dose)
Expected Date:

Dose #
Directly Observed Therapy (DOT) Received
Side Effect check in box if present
Visit Date:
NO Adverse Reaction
Loss of appetite
Nausea or vomiting
Yellow eyes or skin
Diarrhea
Rash/hives
Fever or chills
Sore muscles or joints
Numbness or tingling
Fatigue
Dizziness/fainting
Abdominal pain
Other (describe in progress note)
Tests-blood work (prn)
Medical reconciliation
Nutritional counseling
Smoking cessation
ETOH elimination
Next Appointment
Initials
Rx stop or held
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During the clinic development process, a number of tools and
resources were developed that enabled an organized, efficient,
and quality workflow such as DOT treatment log (Figure 2),
education materials for patients and training materials for staff.
All staff involved in the clinic were required to attend a specific
training session where tuberculosis disease was reviewed
and the ideal treatment regimens were discussed. Individual
refugee population needs were identified and targeted resources
were developed including medication information sheets.
Treatment logs and safe medication handling protocol were
developed and included in subsequent training sessions. Every
person involved in the LTBI clinic was required to demonstrate
competence in the areas of medication provision and handling,
documentation, patient education, communication, and public
health reporting. Certificates of achievement were provided by
the APRN to the clinic staff upon completion of the training and
demonstration of competence.
The new LTBI treatment approach began in early 2016 and
data were collected after University of Louisville Institutional
Review Board (IRB) approval and entered into ARIVE as part
of standard of care documentation. Data were collected in
the LTBI clinic from March-November 2016 and captured for
analysis.

Results
The first six months (March-November 2016) of LTBI clinic
operation are shown in Table 1. Twenty-four patients were
provided with the INH/RPT regimen as standard of care.
Of those, 23/24 (96%) completed the regimen within the
suggested sixteen week time period, a significant improvement
over the 27% completion rate using the previously described
health department referral process. One patient moved after
completing the first four weeks and was lost to follow-up. Six
patients reported adverse events including nausea, diarrhea,
fever, dizziness, and fatigue but none resulted in a regimen
or treatment plan change. There were 24/24 (100%) of the
patients who received their medication through DOT and 8/24
(33%) had at least one DOT episode provided in the home
environment. There were 24/24 (100%) who had at least one
interaction with the GHN as part of the treatment process with
23/24 (96%) having GHN involved in all DOT treatment doses.
The results are demonstrated in Figure 3. One of the 24 spoke
English fluently and preferred that all interactions occur with
the APRN leading the LTBI clinic program. The new LTBI
clinic process resulted in a treatment completion rate of 96%,
and based on the results of the t-test, a statistically significant
improvement over the previously used health department
referral process (96% vs. 27%, p<.001) was identified.

Final Disposition: Date Treatment Completed: __/__/__ Date Treatment Stopped__/__/__ Reason for Stopping: Lost of follow-up__ Moved__Other__Adverse Event__Pending Alternate Tx__

Figure 2 DOT Treatment Log
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Variable

Descriptive Statistics
Demographics
Age, average (range)
38 ( 21-51) n= 24
Gender, male
18 (75%)
Country of Origin
Burma/Myanmar 1 ( 4%)
Cuba 12 (50%)
Democratic Republic of
3 (13%)
Congo
Eritrea 1 ( 4%)
Iraq 4 (17%)
Somalia 1 ( 4%)
Syria 2 (8%)
Preferred Language
Spanish 12 (50%)
Arabic 6 (25%)
Swahili 2 ( 8%)
Chin 1 ( 4%)
English 1 ( 4%)
Kurdish 1 ( 4%)
Somali 1 ( 4%)
Treatment History
Treatment changes, n (%)
0 /24 ( 0%)
Treatment completion n (%) 23/24 (96%)
Medication adverse events 6 /24 (25%)

Figure 3 Patients referred and treated in the LTBI clinic MarchNovember 2016
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Discussion
The first six months of clinic operation identified a number of
challenges including medication access, insurance verification,
lapsing of insurance coverage, space constraints and other
barriers previously identified such as transportation and work
schedule conflicts. This new clinic approach could not resolve
some of these issues, such as those involving insurance, but the
use of personnel able to effectively communicate with the refugee
combined with an active outreach program and emphasis on use
of the 12-week treatment regimen provided new opportunities
for LTBI treatment options unable to be provided through the
traditional public health systems.
Limitations to this study involved the small sample size which
limits the generalizability of the results.

Clinical Implications and Conclusions
This is the first report of an APRN-led LTBI treatment approach
in a refugee-centered medical home using a 12-week treatment
regimen. Aligning the clinic with the medical home enabled
rapid access to other areas of expertise including primary
care and specialty physicians and pharmacists. This level of
collaborative practice served to maximize the use of multiple
skill sets and enabled an effective inter-professional practice
and education platform.
The findings lend themselves to new research initiatives. For
example, can our methods enhance LTBI management for the
larger refugee population? Can these approaches be generalized
to the larger US population? Therefore, further studies are
needed to generate evidence on the effectiveness of interventions
that are tailored to specific risk groups, consider the availability
resources, and take into account the existing infrastructure of
the healthcare system.

Agency for Healthcare Research and Quality (AHRQ). (2012).
Early Evidence on the Patient-Centered Medical Home.
AHRQ Publication N. 12-0020-EF. Available from
https://pcmh.ahrq.gov/sites/default/files/attachments/
Early%20Evidence%20on%20the%20PCMH%202%20
28%2012.pdf
Carrico RM, Goss L, Wiemken TL, Bosson RS, Peyrani P,
Mattingly WA, Pauly A, Ford RA, Kotey S, Ramirez JA.
(2017). Infection prevention and control and the refugee
population, Experiences from the University of Louisville
Global Health Center. Am J Infect Control. 45(6), 673-676.
CDC. (2013). Latent tuberculosis infection: A guide for primary
health care providers. Available from https://www.cdc.gov/
tb/publications/ltbi/pdf/TargetedLTBI.pdf
Colson, P., Franks, J., Sondengam, R., Hirsch-Moverman, Y., &
El-Sadr, W. (2010). Tuberculosis Knowledge, Attitudes, and
Beliefs in Foreign-born and US-born Patients with Latent
Tuberculosis Infection. Journal of Immigrant and Minority
Health, 12(6), 859-866. doi:10.1007/s10903-010-9338-4
Greenwood, M.J. & Warriner, W.R. (2011). Immigrants and the
spread of Tuberculosis in the United States, A hidden cost
of immigration. Population Research and Policy Review,
30(6), 839-859.LoBue, P.A., Mermin, J.H. (2017). Latent
tuberculosis infection, The final frontier of tuberculosis
elimination in the USA. Lancet, S1473-3099 (17), 30248-7.
Available from http://www.thelancet.com/pdfs/journals/
laninf/PIIS1473-3099(17)30248-7.pdf
Office of Refugee Resettlement (2016). FY 2015 Served
Populations by State and Country of Origin (all served
populations). Available from http://www.acf.hhs.gov/
programs/orr/resource/fy-2015-served-populationsby-state-and-country-of-origin-refugees-only
Tsang,
C.A., Langer, A.J., Navin, T.R., Armstrong, L.R. (2017).
Tuberculosis among foreign-born persons diagnosed ≥ 10
years after arrival in the United States, 2010-2015. MMWR.
66(11), 295-298.
Wieland, M., Weis, J., Yawn, B., Sullivan, S., Millington, K.,
Smith, C., . . . Sia, I. (2012). Perceptions of Tuberculosis
Among Immigrants and Refugees at an Adult Education
Center: A Community-Based Participatory Research
Approach. Journal of Immigrant and Minority Health, 14(1),
14-22. doi:10.1007/s10903-010-9391-z

JRGH Vol 2, (1) 2019

3

